Tonix Pharmaceuticals (TNXP)
(Delayed Data from NSDQ)
$0.16 USD
0.00 (2.04%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $0.16 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Tonix Pharmaceuticals Holding Corp falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 8 | 0 | 0 | 0 | 0 |
Cost Of Goods | 5 | 0 | 0 | 0 | 0 |
Gross Profit | 3 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 121 | 112 | 92 | 51 | 29 |
Income After Depreciation & Amortization | -118 | -112 | -92 | -51 | -29 |
Non-Operating Income | 2 | 2 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -117 | -110 | -92 | -50 | -29 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -117 | -110 | -92 | -50 | -29 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -117 | -110 | -92 | -50 | -29 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -114 | -111 | -92 | -50 | -29 |
Depreciation & Amortization (Cash Flow) | 4 | 1 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -118 | -112 | -92 | -51 | -29 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 17.04 | 5.72 | 1.80 | 0.47 | 0.01 |
Diluted EPS Before Non-Recurring Items | -6.85 | -20.44 | -51.92 | -109.82 | -3,859.82 |
Diluted Net EPS (GAAP) | -6.85 | -20.44 | -51.92 | -109.82 | -3,859.82 |
Fiscal Year end for Tonix Pharmaceuticals Holding Corp falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 3.78 | 3.99 | 0.00 | 0.00 |
Cost Of Goods | NA | 2.37 | 2.37 | 0.00 | 0.00 |
Gross Profit | NA | 1.41 | 1.62 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 28.74 | 29.76 | 29.01 | 33.90 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -27.33 | -28.14 | -29.01 | -33.90 |
Non-Operating Income | NA | 0.01 | 0.17 | 0.65 | 0.90 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -27.32 | -27.98 | -28.36 | -33.01 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -27.32 | -27.98 | -28.36 | -33.01 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -27.32 | -27.98 | -28.36 | -33.01 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 31.76 | 15.33 | 10.59 | 10.14 |
Diluted EPS Before Non-Recurring Items | NA | -0.86 | -1.83 | -2.68 | -3.25 |
Diluted Net EPS (GAAP) | NA | 0.91 | -1.83 | -2.68 | -3.25 |